<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR19">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ogura</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Tsukasaki</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Nagai</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Uchida</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Oyama</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Suzuki</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Taguchi</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Maruyama</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Hotta</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Tobinai</surname>
    <given-names>K</given-names>
   </name>
  </person-group>
  <article-title>Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies</article-title>
  <source>Cancer Sci</source>
  <year>2012</year>
  <volume>103</volume>
  <fpage>1290</fpage>
  <lpage>1295</lpage>
  <pub-id pub-id-type="doi">10.1111/j.1349-7006.2012.02287.x</pub-id>
  <pub-id pub-id-type="pmid">22448814</pub-id>
 </element-citation>
</ref>
